SecondStory Health

Healthcare organizations
Quality assurance organizations
Regulatory agencies

SecondStory Health provides your organization with a RATIONAL RESPONSE to the problem of Adverse Event Reporting and Management.

We design and deliver effective software and strategies to discover the hidden but very real causes and costs of healthcare-related adverse events (medication errors, adverse drug reactions, medical errors) and make the needed improvements. Using a customer-focused strategy, SecondStory allows clients to continuously identify, document and improve the safety of healthcare systems. Our clinical and management consulting services link you to a full range of advisory, analytical and database management services, customized to meet the intensity of your needs.

Our PQA-PaLS™ (Pharmacy Quality Assurance-Program and Learning System) tool kit for community pharmacy is an affordable and easy to use resource to help comply with state-level QA regulations and QA requirements in Medicare Part D.

Choose Your Organization Type:

Alerts and Actions
	May 2007 - SecondStory Health to present an audioconference on "Building Safety into Human Research Protection Programs" on May 30th. Register here.
	April 2007 - SecondStory Health announces marketing partnership with the National Alliance of State Pharmacy Associations (NASPA) to promote its adverse event software.
	March 2007 - FDA suspends sale of 2 drugs in 2 days - pergolide (Permax) for Parkinson's Disease and tegaserod (Zelnorm) for bowel disorders after ongoing analysis of adverse reaction data.
	March 2007 - SecondStory Health raises awareness of the risk for medication errors in clinical trials.
	January 2007 - SecondStory Health releases updated version of its PQA-PaLS quality assurance program for community pharmacies.
	July 2006 - IOM releases major report on preventing medication errors-too common, too costly and avoidable.
	April 2006 - Compulsive behaviors – gambling – associated with selected Parkinson’s Disease therapies.
	February 2006 - FDA and Bristol Myers announce new glove-handling precautions for bottles of hydroxyurea (Hydrea® and Droxia®) capsules.
	January 2006 - Quality Assurance requirements in Medicare Part D effective January 1, 2006.
	October 2005 - H5N1 infections, Relenza® and Tamiflu® - Hedging our risks or risking our only hedge?
	May 2005 - FDA announces new warning label changes for fondaparinux (Arixtra®)